Muparfostat

Drug Profile

Muparfostat

Alternative Names: Phosphomannopentaose sulfate; PI-88

Latest Information Update: 15 Feb 2017

Price : $50

At a glance

  • Originator Australian National University
  • Developer Medigen Biotechnology Corporation; Progen Pharmaceuticals; Progen Pharmaceuticals Limited; TBG Diagnostics Limited
  • Class Antineoplastics; Antithrombotics; Mannans; Oligosaccharides
  • Mechanism of Action Fibroblast growth factor inhibitors; Heparanase inhibitors; Heparin cofactor II stimulants; Lipoprotein-associated coagulation inhibitor stimulants; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma; Liver cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Liver cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Liver cancer
  • Phase I/II Solid tumours
  • Discontinued Cardiovascular disorders; Malignant melanoma; Multiple myeloma; Non-small cell lung cancer; Prostate cancer; Thrombosis

Most Recent Events

  • 01 Mar 2016 Medigen Biotechnology terminates a phase III trial in Liver cancer (Adjuvant therapy) in China, Hong Kong, South Korea and Taiwan (SC) (NCT01402908)
  • 02 Jun 2015 Phase-III development for Liver cancer (Adjuvant therapy) is ongoing in China, Hong Kong, South Korea and Taiwan
  • 26 Jan 2012 The State Food and Drug Administration in China approves IND for a phase III trial of muparfostat in Liver cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top